Clinical Trials

Stomach Neoplasms

NCT04559607 2023-12-18

TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

188 enrolled

Carcinoma, Hepatocellular

NCT05099848 2023-08-15

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

21 enrolled

Carcinoma, Hepatocellular

NCT04267549 2023-07-06

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

47 enrolled

Stomach Neoplasms

NCT04930315 2023-06-13

CAPT

78 enrolled

Carcinoma, Hepatocellular

NCT05853172 2023-05-10

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Stomach Neoplasms

NCT04609176 2023-04-21

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

64 enrolled

Stomach Neoplasms

NCT05400902 2023-04-13

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

17 enrolled

Cholangiocarcinoma

NCT05742750 2023-02-24

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

48 enrolled

Biliary Tract Neoplasms

NCT05653817 2022-12-16

Advanced or Metastatic Cholangiocarcinoma

60 enrolled

Cholangiocarcinoma

NCT05290116 2022-08-05

HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

17 enrolled

Cholangiocarcinoma

NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

68 enrolled

Metastatic Gastric Adenocarcinoma

NCT05216237 2022-04-11

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

31 enrolled

Stomach Neoplasms

NCT05225844 2022-02-07

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

150 enrolled

Gastrointestinal Neoplasms

NCT05171309 2021-12-28

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

Carcinoma, Hepatocellular

NCT05095636 2021-10-27

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

102 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT05049681 2021-09-20

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Phase 3 Unknown

234 enrolled

Esophageal Neoplasms

NCT04724226 2021-09-05

C-couple

34 enrolled

Carcinoma, Hepatocellular

NCT05029453 2021-08-31

Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

Phase 4 Unknown

60 enrolled

Stomach Neoplasms

NCT04934618 2021-06-22

A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer

85 enrolled

Stomach Neoplasms

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Metastatic Gastric Adenocarcinoma

NCT04792515 2021-03-11

CCWSA/OAFLAG

67 enrolled

Locally Advanced Gastric Cancer

NCT04665362 2021-01-22

IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC

Phase 1 Unknown

10 enrolled

Carcinoma, Hepatocellular

NCT03154983 2020-12-09

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

48 enrolled

Stomach Neoplasms

NCT04572542 2020-10-01

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

46 enrolled

Locally Advanced or Metastatic Gastric Adenocarcinoma

NCT04446091 2020-06-24

A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)

40 enrolled

Colorectal Neoplasms

NCT04415385 2020-06-04

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

48 enrolled

Pancreatic Neoplasms

NCT04202978 2020-04-16

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

23 enrolled

Hepatic Metastasis of Colorectal Cancer

NCT03397199 2020-04-15

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

120 enrolled

Colorectal Neoplasms

NCT04345783 2020-04-14

Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer

Stomach Neoplasms

NCT04286711 2020-02-27

Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer

52 enrolled

Advanced Gastric Cancer

NCT03603756 2020-02-11

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT03913182 2020-02-05

Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

39 enrolled

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Recurrence

NCT04204577 2019-12-19

The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer

90 enrolled

BCLC Stage B Hepatocellular Carcinoma

NCT04182724 2019-12-03

Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

57 enrolled

Advanced Gastric Cancer

NCT04174339 2019-11-22

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

20 enrolled

Advanced Gastric Adenocarcinoma

NCT04035876 2019-07-29

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

120 enrolled

Carcinoma, Hepatocellular

NCT04014101 2019-07-11

SHR-1210

40 enrolled

Carcinoma, Hepatocellular

NCT03229096 2019-06-28

Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Stomach Neoplasms

NCT03954756 2019-05-17

Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer

Advanced Gastric Cancer

NCT03950141 2019-05-15

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

HER-2 Negatived Gastric Cancer

NCT03912857 2019-04-16

Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer

50 enrolled

Colorectal Neoplasms

NCT03889626 2019-03-26

The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

Phase 3 Unknown

242 enrolled

Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Diseases, Stomach Neoplasms

NCT03857763 2019-02-28

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

40 enrolled

Esophageal Squamous Cell Carcinoma

NCT03271255 2019-01-23

Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)

80 enrolled

Digestive System Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Colorectal Neoplasms

NCT03671265 2019-01-09

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

20 enrolled

Esophageal Neoplasms

NCT03793725 2019-01-04

HZ-T-PD1-APA

Carcinoma, Hepatocellular

NCT03722875 2018-12-19

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

45 enrolled

Carcinoma, Hepatocellular

NCT03718624 2018-10-31

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

36 enrolled